Dataset from A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Nine different formulations of the RSVPreF3 OA investigational vaccine were tested in the
parent study (NCT03814590). Based on safety and immunogenicity data from the parent study,
RSVPreF3 OA investigational vaccine will be evaluated in further clinical research.
Participants in selected groups will be invited to participate in this extension study. All
participants who will be enrolled in the current extension study will receive the RSV
investigational vaccine approximately 18 months after they received their respective dose-2
in the parent study.